Pharmacy Services

Drospirenone-Containing Birth Control Pills

April 12, 2012

After completing a review of recent observational studies, FDA concluded that oral contraceptives containing drospirenone (a synthetic version of progesterone) may be associated with increased risk of blood clots compared to products containing other progestins. The studies showed varying degrees of increased risk of blood clots ranging from no increased risk to a 3-fold higher risk. The actual risk of developing blood clots with drospirenone is not known.

FDA is updating the product labels of birth control pills containing drospirenone (ie., Yaz, Gianvi, Loryna, Yasmin, Ocella, Syeda, Zarah, Beyaz, Safyral). The new labeling will include information on the results of the observational studies and the results of a previously released FDA funded study regarding increased risk of blood clots.

Evaluate women for risk factors for developing blood clots when choosing an oral contraceptive based on patient risk factors. Assess whether the possible increased risk of blood clots associated with drospirenone outweighs the benefits.

Report any related adverse events to FDA’s MedWatch Adverse Event Reporting program online:

Additional information is available at the following links:

April 12, 2012; University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.